Abstract： Treatment for multidrug-resistant tuberculosis (MDR-TB) is extremely difficult. In the recent 50 years, bedaquiline and delamanid have emerged as novel anti-tuberculosis drugs with new action mechanisms, providing additional options for MDR-TB treatment. Relevant studies had shown that these two drugs might prolong the QT interval on electrocardiogram. In this review, the mechanism of prolonging QT interval by these two new anti-tuberculosis drugs, the indications, the contraindications and the precautions under single drug application or multi-drug combination were summarized to provide references for the clinical use of bedaquiline and delamanid in the treatment of MDR-TB.